{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.5","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Mean functionality in study subjects, quantitatively scored using the standardized and validated Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool, which comprehensively assesses aspects of a patient's functionality such as symptoms (e.g., pain, anxiety), social support (e.g., someone to turn to for help), and ability to carry out routine activities (e.g., grocery shopping) or physical exertion (e.g., climbing stairs) was assessed at baseline.\n\nThe score is obtained by inserting patient-specific data into the online calculator found at http://www.mycarg.org/Chemo\\_Toxicity\\_Calculator, which is based on the risk score described in Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457-3465.\n\nThe risk score ranges from 0-19, with 0-5 indicating low risk, 6-9 intermediate risk, and 10-19 high risk for severe (grade \\>2) toxicity.","dispersionType":"Standard Deviation","groups":[{"description":"INDUCTION (28-day cycles for 8 cycles):\n\n* VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15\n* Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15\n* Dexamethasone 40 mg PO days 1,8 and 15\n\nMAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):\n\n* Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21\n* Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15\n\nVelcade: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \\[10,12,14, etc.\\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until","id":"OG000","title":"Velcade, Cyclophosphamide, Revlimid"}],"paramType":"MEAN","populationDescription":"Participants who completed functionality assessment at baseline. Data were incompletely and irregularly collected after baseline so unable to analyze additional time points.","reportingStatus":"POSTED","timeFrame":"baseline","title":"Functionality as Assessed Using the Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}